JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors
Authors
Keywords
-
Journal
DRUGS
Volume 80, Issue 4, Pages 341-352
Publisher
Springer Science and Business Media LLC
Online
2020-02-04
DOI
10.1007/s40265-020-01261-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cardiovascular Safety During Treatment with Baricitinib in Rheumatoid Arthritis
- (2019) Peter C. Taylor et al. Arthritis & Rheumatology
- Tofacitinib: A Review in Psoriatic Arthritis
- (2019) Julia Paik et al. DRUGS
- Baricitinib: The Second FDA-Approved JAK Inhibitor for the Treatment of Rheumatoid Arthritis
- (2019) Amanda Mogul et al. ANNALS OF PHARMACOTHERAPY
- FDA new drug approvals in Q2 2019
- (2019) Lisa Urquhart NATURE REVIEWS DRUG DISCOVERY
- Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain
- (2019) James R. Burke et al. Science Translational Medicine
- Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study
- (2018) G.J. Schmieder et al. BRITISH JOURNAL OF DERMATOLOGY
- Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?
- (2018) Ian C. Scott et al. DRUG SAFETY
- Psoriasis: A STAT3-Centric View
- (2018) et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study
- (2018) Mamitaro Ohtsuki et al. JOURNAL OF DERMATOLOGY
- Topical Janus kinase inhibitors: A review of applications in dermatology
- (2018) Anna-Marie Hosking et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Tofacitinib for the treatment of psoriasis and psoriatic arthritis
- (2018) Anna Berekmeri et al. Expert Review of Clinical Immunology
- Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis
- (2018) Jason E. Hawkes et al. JOURNAL OF IMMUNOLOGY
- Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis
- (2018) Kim Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- OUP accepted manuscript
- (2018) RHEUMATOLOGY
- Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomised VOYAGE 1 and VOYAGE 2 studies
- (2018) K. Reich et al. BRITISH JOURNAL OF DERMATOLOGY
- Abstracts
- (2018) EXPERIMENTAL DERMATOLOGY
- Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
- (2018) Philip Mease et al. LANCET
- Psoriasis pathogenesis and the development of novel targeted immune therapies
- (2017) Jason E. Hawkes et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis
- (2017) Christopher Banfield et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Herpes zoster in psoriasis patients treated with tofacitinib
- (2017) Kevin L. Winthrop et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- JAK inhibitors in dermatology: The promise of a new drug class
- (2017) William Damsky et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
- (2017) Andrew Blauvelt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial
- (2017) Kristian Reich et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis
- (2017) Philip Mease et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors
- (2017) Dafna Gladman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interleukin 17 Family Cytokines: Signaling Mechanisms, Biological Activities, and Therapeutic Implications
- (2017) Leticia Monin et al. Cold Spring Harbor Perspectives in Biology
- Apremilast for the management of moderate to severe plaque psoriasis
- (2017) Ramya Vangipuram et al. Expert Review of Clinical Pharmacology
- Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study
- (2016) V.J. Ludbrook et al. BRITISH JOURNAL OF DERMATOLOGY
- A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis
- (2016) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis
- (2016) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study
- (2016) James Krueger et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis
- (2016) Robert Bissonnette et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study
- (2016) Kim A. Papp et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
- (2016) Kenneth B. Gordon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity
- (2016) C. A. Dendrou et al. Science Translational Medicine
- Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments
- (2016) Fenglong Xie et al. Arthritis & Rheumatology
- Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors
- (2015) W Gao et al. ANNALS OF THE RHEUMATIC DISEASES
- The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
- (2015) John J. O'Shea et al. Annual Review of Medicine
- A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis
- (2015) K. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial
- (2015) R. Bissonnette et al. BRITISH JOURNAL OF DERMATOLOGY
- Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials
- (2015) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- The Immunopathogenesis of Psoriasis
- (2015) Jaehwan Kim et al. DERMATOLOGIC CLINICS
- Small Molecules in the Treatment of Psoriasis
- (2015) Tiago Torres et al. DRUG DEVELOPMENT RESEARCH
- Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome
- (2015) Alexandra Y. Kreins et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
- (2015) Diamant Thaçi et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
- (2015) Christopher E M Griffiths et al. LANCET
- Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
- (2015) Hervé Bachelez et al. LANCET
- Type I/II cytokines, JAKs and new strategies for treating autoimmune diseases
- (2015) Daniella M. Schwartz et al. Nature Reviews Rheumatology
- Immunology of Psoriasis
- (2014) Michelle A. Lowes et al. Annual Review of Immunology
- Mechanisms of Jak/STAT Signaling in Immunity and Disease
- (2014) Alejandro V. Villarino et al. JOURNAL OF IMMUNOLOGY
- Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment
- (2014) Kim Papp et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
- (2014) Richard G. Langley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Critical Role of Jak2 in the Maintenance and Function of Adult Hematopoietic Stem Cells
- (2014) Hajime Akada et al. STEM CELLS
- Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up
- (2013) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- The Interleukin-1 Family: Back to the Future
- (2013) Cecilia Garlanda et al. IMMUNITY
- Conditional Deletion of Jak2 Reveals an Essential Role in Hematopoiesis throughout Mouse Ontogeny: Implications for Jak2 Inhibition in Humans
- (2013) Sung O. Park et al. PLoS One
- Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study
- (2012) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- STAT1 expression and activation is increased in lesional psoriatic skin
- (2012) A. Hald et al. BRITISH JOURNAL OF DERMATOLOGY
- The JAK-STAT Pathway at Twenty
- (2012) George R. Stark et al. IMMUNITY
- IL-12 family cytokines: immunological playmakers
- (2012) Dario A A Vignali et al. NATURE IMMUNOLOGY
- The JAK/STAT Pathway
- (2012) D. A. Harrison Cold Spring Harbor Perspectives in Biology
- Tyrosine kinase 2 (TYK2) in cytokine signalling and host immunity
- (2011) Birgit Strobl Frontiers in Bioscience-Landmark
- Interleukin-2 Receptor Signaling: At the Interface between Tolerance and Immunity
- (2010) Thomas R. Malek et al. IMMUNITY
- A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1
- (2010) Amy Strange et al. NATURE GENETICS
- Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
- (2010) Christopher E.M. Griffiths et al. NEW ENGLAND JOURNAL OF MEDICINE
- Janus kinases in immune cell signaling
- (2009) Kamran Ghoreschi et al. IMMUNOLOGICAL REVIEWS
- JAK3: A two-faced player in hematological disorders
- (2009) Melanie G. Cornejo et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- A Single Nucleotide Polymorphism in Tyk2 Controls Susceptibility to Experimental Allergic Encephalomyelitis
- (2009) K. M. Spach et al. JOURNAL OF IMMUNOLOGY
- The IL-23/Th17 Axis in the Immunopathogenesis of Psoriasis
- (2009) Antonella Di Cesare et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- The Interleukin-8 Pathway in Cancer
- (2008) D. J.J. Waugh et al. CLINICAL CANCER RESEARCH
- The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29
- (2008) Scott Commins et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
- (2008) Craig L Leonardi et al. LANCET
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
- (2008) Kim A Papp et al. LANCET
- Type I Interferon: Potential Therapeutic Target for Psoriasis?
- (2008) Yihong Yao et al. PLoS One
- Inteferons pen the JAK–STAT pathway
- (2008) Christian Schindler et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Structural Biology of Shared Cytokine Receptors
- (2007) Xinquan Wang et al. Annual Review of Immunology
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started